Review: China’s Wholly Foreign-Owned Hospital Pilot — Cities, Approval Steps and Remaining Limits for Investors
Information date: 10 October 2026 — The pilot negative list permits wholly foreign-owned hospitals in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and across Hainan Island. Traditional Chinese
China Medical Device Market Entry: A Practical NMPA Registration Guide for Foreign Manufacturers
Information date: 17 September 2026 — Medical devices in China are managed by risk class: lower-risk products follow a filing route while higher-risk products require registration approval before sale. A foreign manufact
China medical-device classification guide: Intended purpose comes before the product brochure
Information date: 3 September 2026 — China divides medical devices into Classes I, II and III by risk. A foreign manufacturer should not start from a competitor’s product card; it should define intended purpose, structur
China’s Hospital Insurance Overhaul: 3 Moves for Foreign Health Firms
China will pay one uniform rate for 158 common ailments across all hospital tiers, shifting demand to community clinics: 3 moves for foreign health firms.
Beijing’s Pharma Kickback Crackdown: 5 Compliance Moves for Foreign Drugmakers
Beijing is widening its pharmaceutical anti-kickback crackdown beyond hospital procurement to sales teams, conferences, and distributors. Five compliance moves for foreign drugmakers in China's second-largest pharma market.
How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study
How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height: